APVO Stock Overview
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Aptevo Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.74 |
| 52 Week High | US$90.20 |
| 52 Week Low | US$0.67 |
| Beta | 4.93 |
| 1 Month Change | -81.64% |
| 3 Month Change | -89.21% |
| 1 Year Change | -99.12% |
| 3 Year Change | -99.94% |
| 5 Year Change | -99.83% |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy
Sep 19Aptevo meets primary endpoint in early-stage trial for blood cancer therapy
May 26Aptevo: Positive Early Stage Data Makes This Highly Interesting
Dec 02Aptevo gets $50/share takeout offer from shareholder Tang
Nov 18Aptevo Therapeutics rallies 113% as Tang Capital discloses 54% stake
Nov 09Aptevo sells off after clarifying complete response in early-stage study on lead drug
Nov 05Shareholder Returns
| APVO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.3% | 1.5% | 1.2% |
| 1Y | -99.1% | 1.1% | 24.7% |
Return vs Industry: APVO underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: APVO underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| APVO volatility | |
|---|---|
| APVO Average Weekly Movement | 24.6% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: APVO's share price has been volatile over the past 3 months.
Volatility Over Time: APVO's weekly volatility has increased from 17% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 40 | Marvin White | www.aptevotherapeutics.com |
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company’s lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia.
Aptevo Therapeutics Inc. Fundamentals Summary
| APVO fundamental statistics | |
|---|---|
| Market cap | US$1.07m |
| Earnings (TTM) | -US$18.65m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs APVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APVO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$17.11m |
| Gross Profit | -US$17.11m |
| Other Expenses | US$1.54m |
| Earnings | -US$18.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.77 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did APVO perform over the long term?
See historical performance and comparison